Duration of Apixaban (Eliquis) for Apical Thrombus
For left ventricular apical thrombus, treat with apixaban 10 mg twice daily for 7 days, then 5 mg twice daily for a minimum of 3 months, with reassessment at that point for extended therapy based on thrombus resolution and individual risk factors.
Initial Treatment Phase
The FDA-approved dosing for venous thromboembolism applies to left ventricular thrombus management 1:
- Days 1-7: Apixaban 10 mg orally twice daily
- After day 7: Apixaban 5 mg orally twice daily
This higher initial dose is critical for adequate anticoagulation intensity when treating intracardiac thrombus.
Minimum Treatment Duration: 3 Months
Treat for at least 3 months as the baseline duration 2, 3. This aligns with standard anticoagulation principles for thrombotic events, where 3 months represents the minimum treatment phase to address the acute thrombotic burden and allow for thrombus resolution.
At 3 months, obtain repeat imaging (transthoracic echocardiography or cardiac MRI) to assess thrombus resolution 4.
Decision Point at 3 Months
If Thrombus Has Resolved:
Consider extended anticoagulation (beyond 3 months) if:
- Persistent severe LV dysfunction (EF ≤35%)
- Large apical aneurysm present
- Ongoing high thrombotic risk factors
May discontinue anticoagulation if:
- Thrombus completely resolved
- LV function improved (EF >35-40%)
- No apical aneurysm or akinetic segments
- Patient has high bleeding risk
If Thrombus Persists:
Continue anticoagulation and reassess in 1-3 months 4, 5. Most thrombi resolve within 1-3 months of adequate anticoagulation. Case reports demonstrate resolution as early as 1 week, though median time is 24-40 days depending on the agent 5, 6.
If thrombus persists despite 6 months of compliant anticoagulation, consider:
- Switching to warfarin (INR 2-3)
- Cardiac MRI to characterize thrombus (organized vs fresh)
- Evaluation for underlying hypercoagulable state
Extended Therapy Considerations
For patients requiring indefinite anticoagulation (persistent severe LV dysfunction, large apical aneurysm), after 6 months of treatment-dose therapy, you may consider dose reduction to apixaban 2.5 mg twice daily 7, 3. This reduced-dose strategy, validated in the AMPLIFY-EXTEND trial for VTE, offers continued thromboembolic protection with lower bleeding risk.
However, this dose reduction is NOT appropriate for:
- Active/mobile thrombus still present
- Recent thrombus formation (<6 months)
- Very large thrombi (>2 cm)
Monitoring Strategy
- Baseline: Document thrombus size, location, mobility on echo
- 2-4 weeks: Consider early imaging if high embolic risk or symptoms
- 3 months: Mandatory reassessment with imaging
- 6 months: If continuing therapy, reassess need and consider dose reduction
- Annually: If on extended therapy, reassess bleeding/thrombotic risk balance 3
Critical Pitfalls to Avoid
Do not use the 2.5 mg twice daily dose initially - this is only for DVT/PE prophylaxis or extended therapy after 6 months 1. Starting with inadequate dosing risks thrombus propagation and embolization.
Do not assume 4 weeks is sufficient - unlike atrial fibrillation where 3-4 weeks of anticoagulation may clear atrial appendage thrombus, ventricular thrombi often require longer treatment 8. The 3-month minimum is evidence-based.
Medication adherence is paramount - case reports document thrombus formation despite "prescribed" anticoagulation when patients are non-adherent 9. Emphasize compliance and consider more frequent follow-up in unreliable patients.
Parenteral anticoagulation is NOT required before starting apixaban for stable outpatient LV thrombus 1. The 10 mg twice daily initiation dose provides adequate immediate anticoagulation, unlike dabigatran or edoxaban which require parenteral lead-in.
Evidence Quality Note
While current guidelines recommend warfarin as first-line for LV thrombus, the most recent prospective randomized trial (2022) demonstrated apixaban was non-inferior to warfarin for thrombus resolution (94% vs 93% resolution rate) with numerically fewer bleeding events 4. Multiple case series support DOAC efficacy with resolution rates of 81-100% 5. The ACC Expert Consensus acknowledges DOACs are preferred over warfarin for non-cancer-associated thrombosis when appropriate 7.